ATE283921T1 - Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens - Google Patents

Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens

Info

Publication number
ATE283921T1
ATE283921T1 AT00913305T AT00913305T ATE283921T1 AT E283921 T1 ATE283921 T1 AT E283921T1 AT 00913305 T AT00913305 T AT 00913305T AT 00913305 T AT00913305 T AT 00913305T AT E283921 T1 ATE283921 T1 AT E283921T1
Authority
AT
Austria
Prior art keywords
cell
gens
dependent change
tumor specific
herpes
Prior art date
Application number
AT00913305T
Other languages
English (en)
Inventor
E Antonio Chiocca
Richard Y Chung
Original Assignee
Gen Hospital Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gen Hospital Corp filed Critical Gen Hospital Corp
Application granted granted Critical
Publication of ATE283921T1 publication Critical patent/ATE283921T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16611—Simplexvirus, e.g. human herpesvirus 1, 2
    • C12N2710/16641—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16643—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT00913305T 1999-08-31 2000-02-02 Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens ATE283921T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15162199P 1999-08-31 1999-08-31
PCT/US2000/002409 WO2001016331A1 (en) 1999-08-31 2000-02-02 Cell-specific and/or tumor-specific promoter retargeting of herpes gamma 34.5 gene expression

Publications (1)

Publication Number Publication Date
ATE283921T1 true ATE283921T1 (de) 2004-12-15

Family

ID=22539547

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00913305T ATE283921T1 (de) 1999-08-31 2000-02-02 Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens

Country Status (14)

Country Link
EP (1) EP1212428B1 (de)
JP (1) JP4551042B2 (de)
KR (1) KR100701905B1 (de)
AT (1) ATE283921T1 (de)
AU (1) AU781219B2 (de)
CA (1) CA2383372C (de)
DE (1) DE60016429T2 (de)
ES (1) ES2233349T3 (de)
IL (2) IL148360A0 (de)
MX (1) MXPA02002142A (de)
PT (1) PT1212428E (de)
SI (1) SI1212428T1 (de)
WO (1) WO2001016331A1 (de)
ZA (1) ZA200202413B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6897057B1 (en) * 1999-08-31 2005-05-24 The General Hospital Corporation Cell-specific and/or tumor-specific promoter retargeting of herpes γ 34.5 gene expression
EP1486212A1 (de) * 2000-06-01 2004-12-15 Sloan-Kettering Institute For Cancer Research Kombination von einem mutanten Herpesvirus mit Irinotecan zur Behandlung von Krebs
GB0203285D0 (en) 2002-02-12 2002-03-27 Brown Susanne M An herpes simplex virus complex
EP2305710A3 (de) 2002-06-03 2013-05-29 Genentech, Inc. Synthetische Antikörperphagenbibliotheken
GB0326798D0 (en) * 2003-11-17 2003-12-24 Crusade Lab Ltd Methods for generating mutant virus
US7897146B2 (en) 2003-11-17 2011-03-01 Crusade Laboratories Limited Treatment using herpes simplex virus
EP1694852B1 (de) 2003-11-17 2010-10-13 Crusade Laboratories Limited Mutantes herpes-simplex-virus und verwendung davon bei der behandlung von plattenepithelkarzinom
JPWO2011101912A1 (ja) * 2010-02-19 2013-06-17 国立大学法人 東京大学 組み換えヘルペスウイルス及び組換えヘルペスウイルスを含む医薬組成物
EP3011964A1 (de) * 2014-10-24 2016-04-27 Karcinolys Verbindungen und Assoziationen zur Behandlung von Bauchspeicheldrüsenkrebs
EP3429634A1 (de) * 2016-04-15 2019-01-23 Cellectis Verfahren zum engineering von prodrug-spezifischen überempfindlichen t-zellen zur immuntherapie durch genexpression
US10894093B2 (en) 2016-04-15 2021-01-19 Cellectis Method of engineering drug-specific hypersensitive t-cells for immunotherapy by gene inactivation
CN116135972A (zh) * 2021-11-16 2023-05-19 中国科学院深圳先进技术研究院 基于中国hsv临床分离株的溶瘤病毒及其构建方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585096A (en) * 1994-06-23 1996-12-17 Georgetown University Replication-competent herpes simplex virus mediates destruction of neoplastic cells
GB9415320D0 (en) * 1994-07-29 1994-09-21 Medical Res Council Cancer treatment
IL118942A (en) * 1995-07-27 2002-09-12 American Cyanamid Co Nonviolent viruses used as killers - tumors and vaccines
WO1998042195A1 (en) * 1997-03-27 1998-10-01 University Of Cincinnati Replication-competent herpes simplex viruses

Also Published As

Publication number Publication date
KR100701905B1 (ko) 2007-04-02
ZA200202413B (en) 2003-06-25
CA2383372A1 (en) 2001-03-08
CA2383372C (en) 2010-04-13
JP2003508055A (ja) 2003-03-04
JP4551042B2 (ja) 2010-09-22
AU3477400A (en) 2001-03-26
AU781219B2 (en) 2005-05-12
DE60016429D1 (de) 2005-01-05
MXPA02002142A (es) 2003-04-10
IL148360A (en) 2007-12-03
PT1212428E (pt) 2005-03-31
EP1212428A1 (de) 2002-06-12
KR20020092905A (ko) 2002-12-12
SI1212428T1 (en) 2005-06-30
DE60016429T2 (de) 2005-11-24
EP1212428B1 (de) 2004-12-01
ES2233349T3 (es) 2005-06-16
WO2001016331A1 (en) 2001-03-08
IL148360A0 (en) 2002-09-12

Similar Documents

Publication Publication Date Title
ATE283921T1 (de) Zell- und/oder tumor-spezifische promotor- abhängige änderung der gezielten expression des herpes gamma 34.5 gens
HK1091228A1 (en) Methods for making recombinant proteins using apoptosis inhibitors
GR3033534T3 (en) Genetic therapy of diseases of the central nervous system with a cell-specific active substance which is dependent on the cell cycle
ATE412755T1 (de) GENKONSTRUKT DAS FÜR EIN HETEROLOGES ßPRODRUGß- AKTIVIERENDES ENZYM UND FÜR EIN ZELLGERICHTES TEIL KODIERT
ZA942778B (en) Recombinant viruses, and their preparation and use in gene therapy.
DK1681355T3 (da) Sekvensspecifik DNA-rekombination i eukaryote celler
HUP0001937A2 (hu) Új vegyületek, eljárás előállításukra és alkalmazásuk nukleinsavak sejtekbe való bevitelére
MX9801264A (es) Control de la expresion del gen de cd44 para uso terapeutico.
BR9811014A (pt) "região concentrada reguladora de gene especìfica para semente precoce"
NO882854D0 (no) Korreksjon med dobbeltraadet rna av avvikende metabolske spor forbundet med ukontrollerte vekstsykluser for tumorceller og virus.
ES8701224A1 (es) Un metodo para producir citidina y-o desoxicitidina
EP0154566A3 (en) Viral enhancer dna segments
IL126257A (en) Immuno-magnetic cell separation for use in identification of genes associated with site-preferenced cancer methastasis formation
DE50009932D1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
DE60130465D1 (de) Mutierte muskelspezifische enhancer
PT925064E (pt) 5-androsteno-3beta,17alfa-diol como um inibidor do crescimento tumoral
NZ334646A (en) Mammalian REC2 genes and their promoters
BR9911211A (pt) Método para indução de apoptose em células
AU4216599A (en) Hematopoietic progenitor cell gene transduction
DE69840986D1 (de) DNA Fragmente die das Biotin Synthasegen enthalten und deren Verwendung
MX9604240A (es) Transferencia mejorada de adn mediada por virus.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1212428

Country of ref document: EP